Concert Pharmaceuticals Inc (CNCE) was Initiated by Stifel to “Buy” and the brokerage firm has set the Price Target at $23. Stifel advised their investors in a research report released on Jul 1, 2016.
Concert Pharmaceuticals Inc opened for trading at $11.18 and hit $11.38 on the upside on Wednesday, eventually ending the session at $11.29, with a gain of 2.54% or 0.28 points. The heightened volatility saw the trading volume jump to 1,23,876 shares. Company has a market cap of $251 M.
In a different news, on May 16, 2016, Thomas G Auchincloss (director) purchased 2,000 shares at $10.11 per share price. According to the SEC, on May 12, 2016, Roger D Tung (CEO) purchased 19,610 shares at $10.55 per share price. On Dec 17, 2015, Richard Aldrich (director) sold 20,000 shares at $19.76 per share price, according to the Form-4 filing with the securities and exchange commission.
Concert Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company applying its DCE Platform to create novel small molecule drugs. The Company’s approach starts with approved drugs advanced clinical candidates or previously studied compounds that have the potential to be improved with deuterium substitution to enhance clinical safety tolerability and efficacy. It has a pipeline of wholly owned and collaboration programs. The Company has a number of clinical candidates under development such as CTP-656 which is a product candidate for the treatment of cystic fibrosis; AVP-786 which is being investigated for treatment of neurologic and psychiatric disorders including Alzheimers agitation; CTP-730 which is a product candidate for the treatment of inflammatory diseases and JZP-386 which is a product candidate for the treatment of narcolepsy.